NCT05424835进行中（未招募）3 期
A Phase III, Multicenter, Randomized, Open-Label, Parallel Controlled Study of SHR-A1811 Versus Pyrotinib in Combination With Capecitabine for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 269
- 试验地点
- 1
- 主要终点
- PFS（BIRC assessment）between SHR-A1811 4.8mg/kg Q3W and Pyrotinib in combination with Capecitabine.
研究概览
简要总结
The study is being conducted to evaluate whether the efficacy of SHR-A1811 is better than Pyrotinib in combination with Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Able and willing to provide a written informed consent;
- •Unresectable or metastatic HER2 positive breast cancer previously treated with Trastuzumab and Taxane in recurrence and metastasis stage;
- •Documented disease progression;
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- •Life expectancy ≥ 12 weeks.
- •Subject has measurable disease based on RECIST v1.1;
- •Important organ function can meet the criteria (no blood component and cell growth factor treatment within 14 days before the first study drug administration)
- •Pregnancy and Contraception:
- •Women of childbearing potential (WOCBP) must agree to use highly effective contraceptive measures and not to lactate from screening until 7 months after receiving the last treatment.
- •Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to the first study drug administration.
排除标准
- •Subjects with other malignant tumors in the past 5 years (except for the cured skin basal cell carcinoma and cervical carcinoma in situ).
- •There is a third interstitial effusion (e.g., massive ascites, pleural effusion, pericardial effusion) that cannot be controlled by drainage or other methods.
- •Inability to swallow, chronic diarrhea, intestinal obstruction, or other factors that affect drug administration and absorption.
- •Received mitomycin C and nitrosoureas chemotherapy within 6 weeks before the first study drug administration.
- •Any surgery (eg., major surgery for cancer), radiotherapy, chemotherapy, immunotherapy or molecular targeted therapy, biotherapy or other drug clinical trial within 4 weeks; received endocrine therapy within 2 weeks before the first study drug administration.
- •Any concurrent use of immunosuppressant or systemic corticosteroid treatment to achieve immunosuppression purpose (dose of > 10mg/day prednisone or equivalent), and still in use within 2 weeks before the first study drug administration.
- •History of autoimmune disease with the possibility of recurrence or active autoimmune disease; subjects with skin diseases without systematic treatment such as vitiligo, psoriasis, alopecia, or controlled type I diabetes treated with insulin can be included; asthma completely relieved in childhood without any intervention in adult can be included, subjects that requires medical intervention with bronchodilators for asthma cannot be included).
- •History of immunodeficiency including seropositivity for human immunodeficiency virus (HIV) or other acquired or congenital immune-deficient disease, or organ transplantation.
- •Cardiac disease including myocardial infarction within a minimum 6 months before the first study drug administration, severe or unstable angina, symptomatic congestive heart failure (New York Heart Association [NYHA] classes ≥II), or clinically significant supraventricular or ventricular cardiac arrhythmia requiring treatment/intervention.
- •Subjects with known or suspected interstitiallung disease;
- •Active hepatitis B (HBsAg positive and HBV DNA ≥ 500 IU / ml), hepatitis C (hepatitis C antibody positive and HCV RNA higher than the detection limit of the analytical method), hepatic cirrhosis, or severe infections requiring antibiotic, antiviral or antifungal control.
- •Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI CTCAE v5.0 Grade ≤1 at baseline. Subjects with chronic Grade 2 toxicities may be eligible at the discretion of the investigator and discussion with sponsor.
- •Known history of severe allergy to study drug or its components, or allergy to humanized monoclonal antibody products (such as trastuzumab, pertuzumab, etc.).
- •The presence of other serious physical or mental disorders or abnormalities in laboratory tests that may increase the risk of study participation or interfere with study results, as well as patients deemed unsuitable for study participation by the investigator.
研究组 & 干预措施
Treatment group A
Experimental
SHR-A1811 4.8mg/kg
干预措施: SHR-A1811 (Drug)
Treatment group B
Active Comparator
Pyrotinib in combination with Capecitabine.
干预措施: Pyrotinib in combination with Capecitabine. (Drug)
Treatment group C
Experimental
SHR-A1811 6.4mg/kg
干预措施: SHR-A1811 (Drug)
Treatment group D
Active Comparator
Pyrotinib in combination with Capecitabine.
干预措施: Pyrotinib in combination with Capecitabine. (Drug)
结局指标
主要结局
PFS（BIRC assessment）between SHR-A1811 4.8mg/kg Q3W and Pyrotinib in combination with Capecitabine.
时间窗: 6 weeks after the first study drug administration，about 2 years.
次要结局
- AE(about 2 years.)
- PFS（INV assessment）between SHR-A1811 4.8mg/kg Q3W and Pyrotinib in combination with Capecitabine(6 weeks after the first study drug administration，about 2 years.)
- ORR between SHR-A1811 6.4mg/kg Q3W and Pyrotinib in combination with Capecitabine；(about 2 years.)
- DoR between SHR-A1811 6.4mg/kg Q3W and Pyrotinib in combination with Capecitabine；(about 2 years.)
- ORR between SHR-A1811 4.8mg/kg Q3W and Pyrotinib in combination with Capecitabine；(about 2 years.)
- OS between SHR-A1811 4.8mg/kg Q3W and Pyrotinib in combination with Capecitabine；(about 4 years.)
- DoR between SHR-A1811 4.8mg/kg Q3W and Pyrotinib in combination with Capecitabine；(about 2 years.)
- PFS（BIRC assessment）between SHR-A1811 6.4mg/kg Q3W and Pyrotinib in combination with Capecitabine；(6 weeks after the first study drug administration，about 2 years.)
- PFS（INV assessment）between SHR-A1811 6.4mg/kg Q3W and Pyrotinib in combination with Capecitabine；(6 weeks after the first study drug administration，about 2 years.)
- OS between SHR-A1811 6.4mg/kg Q3W and Pyrotinib in combination with Capecitabine；(about 4 years.)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
3 期
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing RegimenHER2-positive Advanced Gastric Cancer or Gastroesophageal Junction AdenocarcinomaNCT06123494Jiangsu HengRui Medicine Co., Ltd.360
招募中
2 期
A Phase Ib/II Study of SHR-A1811 Injection in Breast CancerBreast CancerNCT05353361Jiangsu HengRui Medicine Co., Ltd.402
招募中
3 期
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 MutationsNon-Small Cell Lung Cancer With HER2- MutationsNCT06430437Jiangsu HengRui Medicine Co., Ltd.300
尚未招募
2 期
A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade MeningiomaRecurrent or Progressive High Grade MeningiomaNCT06739213Shanghai Runshi Pharmaceutical Technology Co., Ltd56
已完成
1 期
Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast CancerAdvanced Breast CancerNCT06710990Jiangsu HengRui Medicine Co., Ltd.17